Mr. G. William Basinger, Jr., BS, MS;
Chief Executive Officer
Mr. Basinger brings over 25 years of experience in the biotechnology industry in business development, sales and marketing. Areas of expertise brought to Countervail are new technology acquisition/licensing, strategic and market planning, new product introduction, project management, market research, market assessment, sales force and marketing organization management and distribution networks development. Mr. Basinger has executive management experience in large corporations that include Becton Dickenson, Pharmacia, Analytab (division of American Home Products) and bioMérieux as well as small start up organizations. He has held executive sales, marketing and business development positions with world wide responsibility. In addition to his >25 years of business experience, academic degrees are held in the sciences with a BS from USC and an MS from UNC. Mr. Basinger is affiliated with NorthStar Business Consultants, LLC as a senior partner.
Mr. Ronald C. Lynch, BS, MBA;
Chief Operating Officer
Mr. Lynch offers over 25 years of Sales, Marketing and General Management experience with particular expertise in Traditional and eBusiness Strategic/Tactical Planning, Market Research/Analysis, Project Management, Brand Management, New Product/Technology Marketing and Pricing as well as Sales Force Development and Training. He has successfully designed and supervised the implementation of strategic business and launch plans for over 20 new product categories in six different industries.
Ron has held executive positions with global responsibilities in large established corporations including Johnson & Johnson, Syntex and Becton Dickinson. He has also provided executive services to a number of start-up and early stage organizations. He received his BS degree in Biology from the University of North Carolina Charlotte and his MBA from Loyola College. Mr. Lynch is affiliated with NorthStar Business Consultants, LLC as a senior partner.
Dr. Edson Albuquerque, MD, PhD;
Principle Investigator
Dr.
Edson Xavier de Albuquerque, born in Recife, Pernambuco, Brazil,
earned his M.D. degree from the Sch.Med., Fed. Univ. of Pernambuco in
1959, and earned his Ph.D. degree summa cum laude in Physiol. Pharmacol.
from the Dept. of Biochem., Biophys. & Pharmacol. at the "Escola Paulista
de Medicina" in Sao Paulo, Brazil in 1962. Postdoctoral studies followed
at Tulane University, supported by the Rockefeller Foundation, at the
Univ. Illinois under the guidance of Prof. Klaus Unna, and at the Univ.
Lund (Sweden) with Dr. Stephen Thesleff, at the Karolinska Inst. in
Stockholm with Dr. David Ottoson, and at the Dept. of Anatomy at Umea
with Dr. Ebba Cedergren.
In 1968, he was offered an Honor Position as a Buswell Fellow at the Univ. Buffalo
to join the active group of Sir John Eccles, Prof. Eric Barnard and Prof. David
Triggle. He established his own laboratory, developed a number of fundamental
studies in the field of neuromuscular transmission, and discovered the properties
of many toxins which are used as tools for the characterization of the function
of nicotinic receptors in the neuromuscular junction. He was promoted rapidly,
receiving by 1972 the position of Prof., and by 1973, Prof. Acting Chair of Pharmacology.
In 1974, Dr. Albuquerque accepted the post of Professor & Chair
of the Department of Pharmacology and Experimental Therapeutics, University of
Maryland School of Medicine, Baltimore. There he established his laboratory
for electrophysiological studies of synaptic transmission and developed the department,
which grew from an anonymous department of cell biology to one internationally
recognized for its excellence and bringing in a very high level of research funding.
Dr. Albuquerque has received international recognition for his electrophysiological
research on neurotransmitter receptors in the central and peripheral nervous
systems, including the Order of the Grand Cross and the Rio Branco Award from
Brazil, and in the United States, from the NIH the prestigious Jacob Javits Award
Neuroscience Research Award and the Otto Krayer Award from the American Society
for Pharmacology and Experimental Therapeutics.